Company Overview
Artelo Biosciences, Inc. operates as a clinical stage biopharmaceutical company dedicated to developing and commercializing therapeutics that specifically target lipid-signaling pathways within the United States market. The firm focuses its research and development efforts on its product candidate pipeline, which prominently features ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist designed to address specific therapeutic needs. This enterprise functions within the broader Healthcare sector, specifically classified under the Biotechnology industry, where capital-intensive research and long development cycles are standard operational norms. As a publicly traded entity with a market capitalization of $7.76M and an employee base consisting of seven individuals, Artelo represents a small-cap micro-cap structure typical of early-stage biotechnology ventures. The combination of a negligible market cap and reported annual revenue figures of N/A indicates that the company is currently in a pre-revenue or minimal revenue stage, relying primarily on external capital to fund its clinical development rather than generating significant commercial cash flow.
Financial Health
The company reports an annual revenue (TTM) of N/A, while simultaneously recording a net income (TTM) of $-12,879,000 and an EBITDA of N/A. The substantial gap between the reported revenue of N/A and the significant net loss of $-12,879,000 reveals a cost structure dominated by high fixed costs associated with clinical trials, research personnel, and operational overhead rather than variable production costs. Artelo's free cash flow stands at $-4,168,625, indicating a consistent outflow of cash required to sustain its current operations and development pipeline. This negative free cash flow position implies limited financial flexibility, necessitating ongoing capital raising efforts to prevent liquidity constraints from halting clinical progress. All three margin metrics—the gross margin at 0.0%, the operating margin at 0.0%, and the profit margin at 0.0%—reflect the company's status as a non-profitable entity where revenue generation has not yet offset the heavy investment in research and development. On the balance sheet, the company holds $600,000 in cash against $678,000 in debt, creating a negative net cash position, while the debt-to-equity ratio is listed as N/A due to the lack of positive equity in the traditional sense for ratio calculation. The current ratio of 0.17 further highlights severe short-term liquidity challenges, as current assets are significantly below current liabilities, suggesting an inability to cover immediate obligations without external financing. Furthermore, the return on equity stands at -1625.1% and the return on assets at -190.1%, metrics that mathematically reflect the deep losses being generated relative to the company's book value and asset base.
Valuation Assessment
The trailing P/E ratio is listed as N/A because the company has not achieved profitability, whereas the forward P/E is reported as -11.98, a metric that typically appears when earnings are negative but projected to turn positive in the future. The price-to-book ratio is stated as -5.58, which indicates that the market is valuing the company at a significant discount to its book value, a common characteristic for distressed or pre-revenue biotechnology firms where the intangible value of the pipeline is not fully captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA are both listed as N/A, suggesting that traditional valuation multiples applicable to profitable mature companies are not currently relevant for assessing Artelo's intrinsic value. The stock has experienced extreme volatility over the last year, trading between a 52-week low of $3.15 and a 52-week high of $85.80, illustrating a price range of over 25 times the low point. Although the exact current trading price is not provided in the facts, the wide spread between the high and low suggests that the current price sits at a level that could be either significantly above the low or below the high depending on recent market movements, reflecting the speculative nature of the asset. The beta value of 1.07 indicates that the stock's price volatility is slightly higher than the broader market, moving with a sensitivity that amplifies market swings by approximately 7%.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, indicating that the company has not yet established a track record of consistent growth rates necessary to calculate these percentages. Since the company is not a dividend payer, the dividend yield is N/A and the payout ratio is 0.0%, confirming that the firm reinvests all available capital and operational resources back into its research and development activities rather than distributing income to shareholders. The absence of a dividend yield and the reported net loss imply that the company's primary strategy is to leverage its cash reserves to extend its runway toward potential product approvals rather than providing immediate income returns. Overall, the growth and income profile of Artelo Biosciences is characterized by a total reliance on capital preservation and reinvestment, with no current earnings growth trajectory or dividend distribution mechanism in place.